| Dr Roman Magidenko, MD | |
|
3601 W 13 Mile Rd, Anesthesiology Dept, Royal Oak, MI 48073-6712 | |
| (248) 723-1635 | |
| (248) 723-1681 |
| Full Name | Dr Roman Magidenko |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 39 Years |
| Location | 3601 W 13 Mile Rd, Royal Oak, Michigan |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124090428 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 4301062612 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beaumont Hospital, Troy | Troy, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northstar Anesthesia Of Michigan Iii Pllc | 7911325469 | 526 |
News Archive
Volume 11, Issue 22 of @Oncotarget reported that more and more patients receive first-line treatment with immunotherapy combinations and not all patients respond in metastatic renal cell carcinoma.
When Sasha Costanza-Chock goes through airport security, it is an unusually uncomfortable experience.
Watson Pharmaceuticals, Inc. today reported net income for the first quarter 2012 increased 87 percent to $208.8 million or $1.64 per diluted share on a non-GAAP basis, compared to $111.9 million or $0.89 per diluted share in the first quarter 2011.
Academic medical centers (AMCs) must make systematic changes to improve quality of life—and thus productivity—of their faculty, according to a commentary that will appear in the October 12 issue of Science Translational Medicine.
Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). An analysis of long-term efficacy data demonstrated that blinatumomab produced prolonged remissions in patients with ALL. As of November 2010, the hematologic disease free survival (DFS) was 60%, with a follow-up of up to 27.5 months.
› Verified 5 days ago
| Entity Name | American Anesthesiology Of Michigan Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487609475 PECOS PAC ID: 5294648804 Enrollment ID: O20031110000617 |
News Archive
Volume 11, Issue 22 of @Oncotarget reported that more and more patients receive first-line treatment with immunotherapy combinations and not all patients respond in metastatic renal cell carcinoma.
When Sasha Costanza-Chock goes through airport security, it is an unusually uncomfortable experience.
Watson Pharmaceuticals, Inc. today reported net income for the first quarter 2012 increased 87 percent to $208.8 million or $1.64 per diluted share on a non-GAAP basis, compared to $111.9 million or $0.89 per diluted share in the first quarter 2011.
Academic medical centers (AMCs) must make systematic changes to improve quality of life—and thus productivity—of their faculty, according to a commentary that will appear in the October 12 issue of Science Translational Medicine.
Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). An analysis of long-term efficacy data demonstrated that blinatumomab produced prolonged remissions in patients with ALL. As of November 2010, the hematologic disease free survival (DFS) was 60%, with a follow-up of up to 27.5 months.
› Verified 5 days ago
| Entity Name | Northstar Anesthesia Of Michigan Iii Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972126209 PECOS PAC ID: 7911325469 Enrollment ID: O20200915001990 |
News Archive
Volume 11, Issue 22 of @Oncotarget reported that more and more patients receive first-line treatment with immunotherapy combinations and not all patients respond in metastatic renal cell carcinoma.
When Sasha Costanza-Chock goes through airport security, it is an unusually uncomfortable experience.
Watson Pharmaceuticals, Inc. today reported net income for the first quarter 2012 increased 87 percent to $208.8 million or $1.64 per diluted share on a non-GAAP basis, compared to $111.9 million or $0.89 per diluted share in the first quarter 2011.
Academic medical centers (AMCs) must make systematic changes to improve quality of life—and thus productivity—of their faculty, according to a commentary that will appear in the October 12 issue of Science Translational Medicine.
Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). An analysis of long-term efficacy data demonstrated that blinatumomab produced prolonged remissions in patients with ALL. As of November 2010, the hematologic disease free survival (DFS) was 60%, with a follow-up of up to 27.5 months.
› Verified 5 days ago
| Entity Name | Proper Anesthesia Services Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275292245 PECOS PAC ID: 5294127676 Enrollment ID: O20220114001028 |
News Archive
Volume 11, Issue 22 of @Oncotarget reported that more and more patients receive first-line treatment with immunotherapy combinations and not all patients respond in metastatic renal cell carcinoma.
When Sasha Costanza-Chock goes through airport security, it is an unusually uncomfortable experience.
Watson Pharmaceuticals, Inc. today reported net income for the first quarter 2012 increased 87 percent to $208.8 million or $1.64 per diluted share on a non-GAAP basis, compared to $111.9 million or $0.89 per diluted share in the first quarter 2011.
Academic medical centers (AMCs) must make systematic changes to improve quality of life—and thus productivity—of their faculty, according to a commentary that will appear in the October 12 issue of Science Translational Medicine.
Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). An analysis of long-term efficacy data demonstrated that blinatumomab produced prolonged remissions in patients with ALL. As of November 2010, the hematologic disease free survival (DFS) was 60%, with a follow-up of up to 27.5 months.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Roman Magidenko, MD 3601 W 13 Mile Rd, Anesthesiology Dept, Royal Oak, MI 48073-6712 Ph: (248) 723-1635 | Dr Roman Magidenko, MD 3601 W 13 Mile Rd, Anesthesiology Dept, Royal Oak, MI 48073-6712 Ph: (248) 723-1635 |
News Archive
Volume 11, Issue 22 of @Oncotarget reported that more and more patients receive first-line treatment with immunotherapy combinations and not all patients respond in metastatic renal cell carcinoma.
When Sasha Costanza-Chock goes through airport security, it is an unusually uncomfortable experience.
Watson Pharmaceuticals, Inc. today reported net income for the first quarter 2012 increased 87 percent to $208.8 million or $1.64 per diluted share on a non-GAAP basis, compared to $111.9 million or $0.89 per diluted share in the first quarter 2011.
Academic medical centers (AMCs) must make systematic changes to improve quality of life—and thus productivity—of their faculty, according to a commentary that will appear in the October 12 issue of Science Translational Medicine.
Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). An analysis of long-term efficacy data demonstrated that blinatumomab produced prolonged remissions in patients with ALL. As of November 2010, the hematologic disease free survival (DFS) was 60%, with a follow-up of up to 27.5 months.
› Verified 5 days ago
Dr. Daniel Sapeika, M.D. Anesthesiology Medicare: May Accept Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-458-0400 Fax: 248-458-0310 | |
Joshua Jones, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-1905 | |
Paul Villalba, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-1905 | |
Dr. Paul M O Leary, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 3601 W 13 Mile Rd, Anesthesiology Dept, Royal Oak, MI 48073 Phone: 248-723-1635 Fax: 248-723-1681 | |
Shereen M Saad, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-0833 | |
Cindy Lin, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-0833 | |
Dominique Michelle Donatelli, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 3601 W Thirteen Mile Rd, Beaumont Hospital Gme Office, Royal Oak, MI 48073 Phone: 248-898-5000 |